Let’s first explain
API industry chain company combing
Next, we will talk about A-share-related companies. China has 29 API and intermediates companies, with a market value of more than 400 billion yuan, accounting for about 1% of the market value of the pharmaceutical sector.
From the perspective of PE valuation, Menovartis, Shanhe Pharmaceutical, Efan Pharmaceutical, and other valuations are low; from the perspective of company texture, Kleene, Xinheicheng, Menovartis are superior; from API-preparation integration, Zhejiang Pharmaceutical, from a higher export perspective, Menovartis, Kelene and Pharmaceutical Technology are higher.
Although there are 29 API and intermediates companies in China, there are only 11 real API companies.
A Shares of real API companies
1, Jianyou shares: one of the leading heparin API, the company actively layout of new varieties of preparations.The company’s main business: the products are mainly a whole series of heparin products, covering high-quality heparin API, low molecular heparin, and other major preparations, and cooperating with the research and development, production, and sales of anti-tumor drugs and other drugs. The company is also one of the few heparin manufacturers certified by the FDA and EU EDQM.
2, Proo Pharmaceutical: “API + preparation +CDMO” integration coordinated development. The company’s main business: API, contract research and development production service (CDMO), and preparation business, the products are mainly concentrated in cardiovascular and cerebrovascular, anti-infection, anti-tumor, and other treatment fields. There are more than 70 large-scale production varieties of raw materials of the company, and 11 varieties of more than 100 million yuan. Hydroxy acid, African, sartan, D-ethyl ester, and other varieties account for the absolute global market share.
3. Si Tail: The domestic contrast agent leader. The main products of the company are the research and development and production of non-ionic iodocontrast agents and quinolone antibiotics and other drugs, among which the main products of iodine contrast agent API are iodixanol, iodixanol, etc.; the main products of quinolone are levofloxacin, levofloxacin hydrochloride, etc.
4. Ju Xian Pharmaceutical: steroidal hormone leader.The company’s main business: the largest steroidal hormone manufacturer in China, mainly producing corticoid drugs, sex hormone drugs (gynecological and family planning drugs), and anesthesia and my tone drugs.
5, Tianyu shares: the new production capacity is gradually released, driving the rapid growth of the company.The company’s main business: cardiovascular and cerebrovascular drugs, glucose-lowering drugs, lipid-lowering drugs, anticoagulation drugs, and anti-asthma drugs, and other pharmaceutical intermediates and raw material drugs, among which valsartan is one of the world’s largest suppliers.
6. Fuxiang shares: stable antibiotic status, and actively expands new business. Company main business: chemical drug research and development, production, sales and service, the company constantly establish and improve the production chain, to API upstream and downstream extension, through research and development and process improvement, provide global customers with high-quality products, recognized by many well-known customers at home and abroad, the company has gradually become one of the global shubutan, his Jobberman, one of the main suppliers.
7, Jiuzhou Pharmaceutical: CDMO+API integrated platform of chemical Pharmaceutical.The main business of the company: leading chemical API and CDMO production enterprises in China, especially in the field of small molecule chemical drugs with obvious technology and scale advantages. After the acquisition of Suzhou Novartis Factory, the company has accelerated its transformation and upgraded to CDMO, which is expected to become an important growth point of the company in the future.
8, Huahai Pharmaceutical: “Integrated development of intermediate + API + preparation”.The company’s main business: the research and development, production, and sales of multi-agent agents, biological drugs, innovative drugs, and characteristic raw drugs. Its products cover the cardiovascular, spiritual, and antiviral fields, and it is also one of the main manufacturers of cardiovascular and psychiatric medical products in the world. In 2018, affected by valsartan, revenue and performance increased 2% and-83%, respectively. In addition, the company has vigorously expanded the downstream preparation business, in recent years has obtained a number of product approvals, is expected to become an important growth point of the company.
9, Menovartis: “CMO/CDMO+ API / preparation integration” driven.Company’s main business: set pharmaceutical intermediates, pharmaceutical API and finished drug research and development, pilot, production, sales as one of the comprehensive pharmaceutical enterprises, products involving cardiovascular, central nervous system, digestive system, elderly diseases, and antiviral system, leading products are valsartan, losartan, irbesartan, perindopril, rosuvastatin, atorvastatin, clopidogrel and esomeprazole, and other raw drugs and intermediates.
10, Hepura: one of the main suppliers of heparin sodium API worldwide. Company main business: committed to heparin sticky polysaccharide products of research and development, production, and sales, with heparin sodium API, enoxaparin sodium API and preparations as the main products, customers in North America, Europe, Asia, South America, Africa, the company is also the world’s largest production, equipped with the most advanced global range of heparin sodium API suppliers.
11, Aoxiang Pharmaceutical: obvious advantages, in a period of rapid rise. The company’s main business is liver disease, respiratory system, cardiovascular and cerebrovascular, high-end fluorine products, prostaglandins, antibacterial, gout, and anti-tumor. The company’s products have passed the registration and certification of the pharmaceutical administration departments of EU GMP, FDA, and other countries and regions.
API is in the middle and upstream of the pharmaceutical industry chain, which is the basis for ensuring drug supply and meeting people’s drug needs. With the development of the economy, the growth of the total global population, the accelerated social aging and the deteriorating living environment, the frequent diseases lead to the increasing people’s awareness of health care and the continuous expansion of the scale of the global medical market. The expansion of the drug market scale has also directly led to the global scale of chemical API to rise year by year. Although global economic development has slowed in recent years, the global pharmaceutical industry, the global pharmaceutical industry is still higher than the global GDP growth. As the middle and upstream link of the pharmaceutical industry, the development of the API industry is inseparable from the development of the pharmaceutical industry.
Post time: Oct-25-2021